Summary
73 / 100 · Bulios Score
What speaks for it
- Out of every 100 INR of revenue, 8.0 INR is left as net profit.
- It could repay all its net debt from 0.5 years of operating profit.
What to watch
- Earnings per share fell by 31% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- It reports a profit, yet spends more cash than it brings in.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 7.5 INR for 1 INR of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (INR)
Diluted EPS (INR)
Revenue grew by 8.4% a year over 5 years. Over the last 3 years it grew by 0.5% a year. Earnings per share fell by 31% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 INR of revenue goes
- Cost of sales 70 INR
- Sales and administration 14 INR
- Taxes and other 1.6 INR
- Net profit 8.0 INR
Net profit, industry median (Chemicals - Specialty) 6.1 INR
Out of every 100 INR of revenue, 8.0 INR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 1.26%
- Paid out of profit
- 9.5%
You receive ₹1.50 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail